Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07186192 · ClinicalTrials.gov registry record · Phase 3
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
A Phase 3 study of Hematologic Malignancies, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 1
- Study location
NCT07186192 is a Phase 3 study of Hematologic Malignancies that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 190 participants, below the 2,708-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07186192, a Phase 3 study of Hematologic Malignancies, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family caregivers (FCGs).
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Educational Intervention
- PROCEDURE Health Telemonitoring
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2029-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07186192
The ClinicalTrials.gov registry entry for NCT07186192 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,708-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (93% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT07186192 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07186192 about?
NCT07186192 is a clinical study titled "Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy". The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family caregivers (FCGs).
What is the current status of trial NCT07186192?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2026-01-14. Estimated completion is 2029-03-29.
What conditions does trial NCT07186192 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT07186192?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Educational Intervention (OTHER), Health Telemonitoring (PROCEDURE).
Who is sponsoring clinical trial NCT07186192?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07186192 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RECRUITING · Phase 3
-
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
COMPLETED · Phase 3
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.